{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:17:30Z","timestamp":1773278250886,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1080\/14653240310001307","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T18:42:16Z","timestamp":1062096136000},"page":"190-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Is retroviral gene marking too dangerous to use?"],"prefix":"10.1016","volume":"5","author":[{"given":"M.K.","family":"Brenner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1080\/14653240310001307_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1080\/14653240310001307_bib2","unstructured":"Orkin SH, Morulsky AG. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http:\/\/www4.od.nih.gov\/oba\/rac\/panelrep.htm visited 13th May 2003."},{"key":"10.1080\/14653240310001307_bib3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/0140-6736(93)92122-A","article-title":"Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients","volume":"342","author":"Brenner","year":"1993","journal-title":"Lancet"},{"key":"10.1080\/14653240310001307_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/hum.1990.1.1-73","article-title":"The N2-TIL human gene transfer clinical protocol","volume":"1","author":"Rosenberg","year":"1990","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001307_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans-immunotherapy of patients with advanced mela noma, using tumor-infiltrating lymphocytes modified by retro-viral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1080\/14653240310001307_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(93)92560-G","article-title":"Gene-marking to trace origin of relapse after autologous bone marrow transplantation","volume":"341","author":"Brenner","year":"1993","journal-title":"Lancet"},{"key":"10.1080\/14653240310001307_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/hum.1991.2.4-359","volume":"2","author":"Deisseroth","year":"1991","journal-title":"Hum Gene Tber"},{"key":"10.1080\/14653240310001307_bib8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V85.11.3048.bloodjournal85113048","article-title":"Retrovirally marked CD34-enriched peripheral blood and marrow cells contribute to long term engraftment after autologous transplan tation","volume":"85","author":"Dunbar","year":"1995","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"10.1080\/14653240310001307_bib10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood.V92.4.1073","article-title":"Autologous stem cell transplantation in acute myelocytic leukemia","volume":"92","author":"Gorin","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib11","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood.V89.7.2233","article-title":"The biology and clinical uses of blood stem cells","volume":"89","author":"To","year":"1997","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0889-8588(05)70104-0","article-title":"Autologous stem-cell transplantation for solid tumors in adults","volume":"13","author":"Nieto","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1080\/14653240310001307_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0889-8588(05)70102-7","article-title":"Autologous hematopoietic cell trans plantation in non-Hodgkin's lymphoma","volume":"13","author":"Johnston","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1080\/14653240310001307_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bmt.1701051","article-title":"Should we purge? [editorial; comment]","volume":"21","author":"Bensinger","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/14653240310001307_bib15","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood.V88.9.3314.bloodjournal8893314","article-title":"Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangements in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplan tation","volume":"88","author":"Zwicky","year":"1996","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/hum.1991.2.2-137","article-title":"Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the bioloby of marrow reconstitu-tion and the mechanism of relapse","volume":"2","author":"Brenner","year":"1991","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001307_bib17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V84.2.380.380","article-title":"Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells","volume":"84","author":"Rill","year":"1994","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/hum.1996.7.11-1323","article-title":"Retroviral gene transfer in autologous bone marrow transplantation for adult acute leuke mia","volume":"7","author":"Cornetta","year":"1996","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001307_bib19","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML","volume":"83","author":"Deisseroth","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/hum.1991.2.3-257","article-title":"A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse","volume":"3","author":"Santana","year":"1991","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001307_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/hum.1992.3.3-305","article-title":"Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia","volume":"3","author":"Cornetta","year":"1992","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001307_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1080\/14653240310001307_bib23","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/4716","article-title":"In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [comments]","volume":"5","author":"Brodie","year":"1999","journal-title":"Nat Med"},{"key":"10.1080\/14653240310001307_bib25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr vims-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001307_bib26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lympho-proliferative disease after successful correction of CD 40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:09:35Z","timestamp":1761430175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324903711372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003]]}},"alternative-id":["S1465324903711372"],"URL":"https:\/\/doi.org\/10.1080\/14653240310001307","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is retroviral gene marking too dangerous to use?","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1080\/14653240310001307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}